Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Misoprostol + oxytocin versus oxytocin alone for prevention of primary postpartum hemorrhage after vaginal delivery
PACTR202506646284255Not yet recruiting
- Sponsor
- Ogonna Ezenwafor
- Start
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in postpartum hemorrhage (PPH) comparing Misoprostol + oxytocin with Oxytocin + placebo (2 arms). Primary endpoint: Mean postpartum blood loss between the groups. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
misoprostoloxytocin
03
Conditions
postpartum hemorrhage (PPH)
Beyond the preview
Go deeper on PACTR202506646284255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202506646284255.